Surrogate markers of clinical endpoints in clinical trials of heart failure
In HF trials, most surrogate markers, including NPs and echocardiographic measures were only weakly or moderately correlated with treatment effects on all-cause mortality. There is insufficient evidence to support the use of a single biomarker or echocardiographic measure in regulatory trials of HF.
Authors
- N. Raftopulos
- Phidias Rueter (ORCID: https://orcid.org/0000-0001-5140-6738)
- T. Hibbert
- R. Abdo
- Christian Abhayaratna
- Nelson Wang
- Sarah Ishak
- Muthiah Vaduganathan
Institutions
- Brigham and Women's Hospital (US)
- The University of Sydney (AU)
- Victor Chang Cardiac Research Institute (AU)
- Royal Prince Alfred Hospital (AU)
- St Vincent Hospital (US)
- Westmead Hospital (AU)
- St Vincent's Hospital Melbourne (AU)
- St Vincent's Hospital Sydney (AU)
- St Vincent’s Private Hospital Sydney (AU)
- The George Institute for Global Health (AU)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1093/ejhf/xuag033
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00